Interleukin-5 Receptor alpha-directed Cytolytic Antibody drugs

1 medication in the FDA established pharmacologic class “Interleukin-5 Receptor alpha-directed Cytolytic Antibody”.

DrugTypeNDC products
Fasenra
Benralizumab
Rx3